Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

Itamar Raz, Peter W F Wilson, Krzysztof Strojek, Irina Kowalska, Velimir Bozikov, Anselm K Gitt, György Jermendy, Barbara N Campaigne, Lisa Kerr, Zvonko Milicevic, Scott J Jacober, Itamar Raz, Peter W F Wilson, Krzysztof Strojek, Irina Kowalska, Velimir Bozikov, Anselm K Gitt, György Jermendy, Barbara N Campaigne, Lisa Kerr, Zvonko Milicevic, Scott J Jacober

Abstract

Objective: Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI).

Research design and methods: Patients (type 2 diabetes, aged 30-75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l).

Results: A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1-1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8-1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 +/- 0.1 vs. 7.8 +/- 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmol/l; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmol/l; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group.

Conclusions: Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.

Figures

Figure 1
Figure 1
Fraction of patients who did not experience a first primary (combined cardiovascular) adjudicated outcome versus days in trial by treatment strategy (PRANDIAL versus BASAL).
Figure 2
Figure 2
Glycemic measures. A: Mean ± SD A1C at each visit by treatment strategy (PRANDIAL versus BASAL). B: Seven-point mean self-monitored blood glucose profiles at baseline (dotted line) and throughout the study (postrandomization, solid line) by treatment strategy (PRANDIAL versus BASAL).

References

    1. Stamler J, Vaccaro O, Neaton JD, et al.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444, 1993
    1. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234, 1998
    1. Eberly LE, Cohen JD, Prineas R, et al.: Impact of diabetes and incident nonfatal cardiovascular disease on 18-year mortality. Diabetes Care 26:848–854, 2003
    1. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412, 2000
    1. Holman RR, Paul SK, Bethel MA, et al.: 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589, 2008
    1. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 287:2570–2581, 2002
    1. Lakka HM, Laaksonen DE, Lakka TA, et al.: Metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716, 2002
    1. DECODE: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405, 2001
    1. Meigs JB, Nathan DM, D’Agostino RB Sr, et al.: Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850, 2002
    1. Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1–7, 2005
    1. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494, 2003
    1. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512–1515, 1997
    1. Milicevic Z, Raz I, Strojek K, et al.: Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with type 2 diabetes mellitus (HEART2D) study design. J Diabetes Complications 19:80–87, 2005
    1. Esposito K, Giugliamo D, Nappo F, et al.: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214–219, 2004
    1. Shimabukuro M, Chinen I, Higa N, et al.: Effects of dietary composition on postprandial endothelial function and adiponectin concentrations in healthy humans: a crossover controlled study. Am J Clin Nutr 86:923–928, 2007
    1. Mita T, Watada H, Shimizu T, et al.: Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 27:2456–2462, 2007
    1. Alssema M, Schindhelm RK, Dekker JM, et al.: Postprandial glucose and not triglyceride concentrations are associated with carotid intima media thickness in women with normal glucose metabolism: the Hoorn prandial study. Atherosclerosis 196:712–719, 2008
    1. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289, 2005
    1. Malmberg K, Ryden L, Wedel H, et al.: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650–661, 2005
    1. Van den Berghe G: Insulin vs. strict blood glucose control to achieve a survival benefit after AMI? Eur Heart J 26:639–641, 2005
    1. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559, 2008
    1. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572, 2008
    1. Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139, 2009
    1. Juutilainen A, Lehto S, Rönnemaa T, et al.: Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 31:714–719, 2008
    1. Ceriello A, Assaloni R, Da Ros R, et al.: Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 111:2518–2524, 2005

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner